by David Wallace Dr. Ghaith Abu-Zeinah, Assistant Professor at Weill Cornell Medical College, Silver MPN Center is our MPN specialist answering this important question. David Wallace, PV Reporter, is your host and patient advocate. TRANSCRIPT | Has PV become a disease of the middle-aged? David: For many years PV been considered an older person’s disease. […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
Polycythemia Vera patient advocate on living with MPN, Diane’s story
September Blood Cancer Awareness Month Spotlight by David Wallace David Wallace, your host with PV Reporter, talks to fellow PV patient advocate Diane Rose about living with Polycythemia Vera. Diane shares her patient story as we talk about how she was diagnosed, treatment, ET shifting to PV, being your own advocate, fear of needles and […]
Differential cytokine network profile in Polycythemia Vera and Secondary Polycythemia
Authors: Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Maria Gabriela Berzoti-Coelho, Raquel Tognon, Natalia de Souza Nunes, Belinda Simões, Ítalo Sousa Pereira, Daniela Carlos, Lucia Helena Faccioli, Lorena Lobo de Figueiredo-Pontes, Fabiani Gai Frantz & Fabíola Attié de Castro Scientific Reports volume 10, Article number: 7032 (2020) Abstract Polycythemia vera (PV) is a clonal disorder resulting from neoplastic transformation of hematopoietic stem cells, while secondary polycythemia (SP) is a disease characterized by increased absolute […]
PTG-300 Hepcidin Mimetic Receives FDA Orphan Drug Designation for Treatment of Polycythemia Vera
NEWARK, Calif., June 17, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis. “Receiving […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »
